ATXA Therapeutics Limited (ATXA) is delighted to announce that it is honoured to receive grant and equity funding through the prestigious European Innovation Council (EIC) Accelerator programme. In her recent News Alert announcing the latest recipients, Mariya Gabriel, European Commissioner for Innovation and Research explained that “The EIC Accelerator and EIC Fund provides a unique combination of grants, investments, and business acceleration services to Europe’s most promising deep tech start-ups”.
ATXA is set to receive significant blended (€10.5M in grant and equity) financing from a highly competitive field of over 1000 applications, with only 75 companies across 21 countries successful in the latest funding round.
ATXA is a clinical-stage pharmaceutical company committed to providing innovative, life-changing treatments for certain cardiopulmonary diseases. Our focus is on the clinical advancement of novel, rationally designed first-in-class antagonists of the Thromboxane Receptor (TP), a key driver of such diseases of the heart and lungs. Within our proprietary drugs pipeline, our lead drug NTP42 is in clinical development initially for the treatment of Pulmonary Arterial Hypertension (PAH) and related cardiopulmonary diseases, but also has platform potential to treat many other clinical indications with high unmet medical needs. NTP42 was recently tested in a first-in-human Phase I clinical trial and was found as safe and well-tolerated. It was also confirmed to be pharmacologically active at low oral doses, and that taking the drug once daily with or without food is sufficient for clinical efficacy.
On hearing of the award, ATXA’s Founder and CEO Prof. Therese Kinsella said “This very positive news is a great acknowledgement of the achievements, vision, and standing of ATXA with the EIC and their external expert evaluators, further endorsing us as a disruptive, innovative technology within the wider EC community. Driven by innovative research, our aim is to bring accessible, affordable, and life-changing treatments to patients with PAH and related cardiopulmonary diseases, offering them new hope and improving their overall quality-of-life. This financing by the EIC will be transformational for ATXA in enabling us to achieve this priority mission for the patient.”
For more information, please contact:
Email: info@atxatherapeutics.com